Biomark Med. 2007 Oct;1(3):399-417.

Use of pharmacokinetic/pharmacodynamic biomarkers to support rational cancer drug development.

Source

Signal Transduction & Molecular Pharmacology Team, Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, SM2 5NG, UK.

Abstract

The process of drug development in oncology has struggled to alter at a pace in keeping with the rapid discovery and testing of agents that act on a wide variety of molecular targets. The rational development of such agents requires an understanding of drug effect(s) on their purported target. It is likely that testing these drugs in a framework designed to examine cytotoxic agents will fail to establish their full potential. We discuss how data gained from biomarker investigation might impact on drug development and provide examples that highlight the development, validation and use of pharmacokinetic, and especially pharmacodynamic biomarkers as drug development moves from the laboratory into clinical testing. The challenges of performing assays to satisfy regulatory requirements have been the subject of much debate. We recommend the implementation of appropriate, fit-for-purpose biomarkers in clinical trials of all new cancer drugs.

PMID:: 20477383; [PubMed - in process]

LinkOut - more resources

Full Text Sources

Other Literature Sources

COS Scholar Universe

Supplemental Content

Related citations

Review Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development. [Cancer J. 2009]
Review Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development.
Tan DS, Thomas GV, Garrett MD, Banerji U, de Bono JS, Kaye SB, Workman P. Cancer J. 2009 Sep-Oct; 15(5):406-20.
Review Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies. [J Natl Cancer Inst. 2006]
Review Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies.
Workman P, Aboagye EO, Chung YL, Griffiths JR, Hart R, Leach MO, Maxwell RJ, McSheehy PM, Price PM, Zweit J, et al. J Natl Cancer Inst. 2006 May 3; 98(9):580-98.
Review Biomarkers, validation and pharmacokinetic-pharmacodynamic modelling. [Clin Pharmacokinet. 2003]
Review Biomarkers, validation and pharmacokinetic-pharmacodynamic modelling.
Colburn WA, Lee JW. Clin Pharmacokinet. 2003; 42(12):997-1022.
Review Pharmacodynamic biomarkers for molecular cancer therapeutics. [Adv Cancer Res. 2007]
Review Pharmacodynamic biomarkers for molecular cancer therapeutics.
Sarker D, Workman P. Adv Cancer Res. 2007; 96:213-68.
Review The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones. [Cancer Chemother Pharmacol. 2003]
Review The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
Workman P. Cancer Chemother Pharmacol. 2003 Jul; 52 Suppl 1:S45-56. Epub 2003 Jun 18.

See reviews... See all...

Cited by 2 PubMed Central articles

Identification of direct target engagement biomarkers for kinase-targeted therapeutics. [PLoS One. 2011]
Identification of direct target engagement biomarkers for kinase-targeted therapeutics.
Paweletz CP, Andersen JN, Pollock R, Nagashima K, Hayashi ML, Yu SU, Guo H, Bobkova EV, Xu Z, Northrup A, et al. PLoS One. 2011; 6(10):e26459. Epub 2011 Oct 24.
A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors. [Clin Cancer Res. 2011]
A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors.
Pacey S, Wilson RH, Walton M, Eatock MM, Hardcastle A, Zetterlund A, Arkenau HT, Moreno-Farre J, Banerji U, Roels B, et al. Clin Cancer Res. 2011 Mar 15; 17(6):1561-70. Epub 2011 Jan 28.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Use of pharmacokinetic/pharmacodynamic biomarkers to support rational cancer dru...
Use of pharmacokinetic/pharmacodynamic biomarkers to support rational cancer drug development.
Biomark Med. 2007 Oct ;1(3):399-417.

PubMed
Meeting the challenges in screening.
Meeting the challenges in screening.
Drug Discov Today. 2002 Dec 1 ;7(23):1162-4.

PubMed
Calcification properties of saline-filled breast implants.
Calcification properties of saline-filled breast implants.
Plast Reconstr Surg. 2001 Feb ;107(2):356-63.

PubMed
Practical approaches to proteomic biomarkers within prostate cancer radiotherapy...
Practical approaches to proteomic biomarkers within prostate cancer radiotherapy trials.
Cancer Metastasis Rev. 2008 Sep ;27(3):375-85.

PubMed
MPH1, a yeast gene encoding a DEAH protein, plays a role in protection of the ge...
MPH1, a yeast gene encoding a DEAH protein, plays a role in protection of the genome from spontaneous and chemically induced damage.
Genetics. 2000 Jul ;155(3):1069-81.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Display Settings:

Send to:

Use of pharmacokinetic/pharmacodynamic biomarkers to support rational cancer drug development.

Source

Abstract

LinkOut - more resources

Full Text Sources

Other Literature Sources

Supplemental Content

Related citations

Cited by 2 PubMed Central articles

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information